The concept of the GPOH-HD 2003 therapy study for pediatric Hodgkin's disease: evolution in the tradition of the DAL/GPOH studies.
Today it is possible to cure more than 90 % of children and adolescents with Hodgkin's disease with a combination of radiotherapy and chemotherapy. Since the DAL-HD 82 study, the main scientific focus has been on avoiding late effects such as the OPSI syndrome, late complications involving the heart, lungs, thyroid and/or gonads particularly sterility in men and premature onset of menopause in women, and the prevention of secondary malignancies. The GPOH-HD 2003 study will introduce FDG-PET to the initial diagnostic program and the assessment of response to therapy in order to evaluate further possibilities for reducing therapy. In this context, the central review of all clinical and radiological findings, systematically done since the DAL-HD 90 study, will be increasingly relevant in maintaining standardised stage classification and therapy group assignment which was established by the preceding studies. Continuing in the direction of the earlier studies, the indications for radiotherapy will be restricted even further. In the early stages (treatment group 1) patients with CR or a negative FDG-PET at the end of chemotherapy will receive no radiotherapy in order to reduce the risk of a secondary malignancy. In a randomized comparison, procarbazine will be replaced by dacarbazine in the COPP cycles to determine whether sterility in men and premature onset of menopause in women can be avoided by elimination of procarbazine while retaining the same clinical efficacy. Finally, relapse therapy is to be tailored according to the time of relapse, the initial therapy group, and the patient's response to the relapse therapy with more patients receiving autologous transplantation in order to further improve the results of relapse treatment.
Körholz
D
D
Division of Pediatric Hematology and Oncology, Clinic and Policlinic for Children and Adolescents, University of Leipzig Medical Center, Germany. koerd@medizin.uni-leipzig.de
Claviez
A
A
Hasenclever
D
D
Kluge
R
R
Hirsch
W
W
Kamprad
F
F
Dörffel
W
W
Wickmann
L
L
Papsdorf
K
K
Dieckmann
K
K
Kahn
T
T
Mauz-Körholz
C
C
Dannenberg
C
C
Pötter
R
R
Brosteanu
O
O
Schellong
G
G
Sabri
O
O
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D019788:Fluorodeoxyglucose F18; D005858:Germany; D006689:Hodgkin Disease / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy*; D006801:Humans; D015337:Multicenter Studies as Topic; D009367:Neoplasm Staging; D009381:Neoplasms, Radiation-Induced / Q000517:prevention & control; D016609:Neoplasms, Second Primary / Q000517:prevention & control; D015996:Survival Rate; D014055:Tomography, Emission-Computed
D019788:Fluorodeoxyglucose F18